Seres therapeutics receives feedback from fda on ser-155 allogeneic hematopoietic stem cell transplant (allo-hsct) development approach

Fda has provided input on key elements of the ser-155 allo-hsct clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (bsis) as of 30 days post hsct in the next study
mcrb Ratings Summary
mcrb Quant Ranking